Clinical Trials

Inclusion Criteria:

• In both trials of Aim 2, twenty adults (≥18 years) per trial will be recruited who are newly diagnosed with OSA and speak English.
• In both trials, we will purposely recruit samples balanced by biological sex and OSA severity (apnea hypopnea index: 5-14 vs. ≥ 15).
• Inclusion Criteria are the same for both Aim 2 trials; Adult patients from MCCSM sites who:
  • Are diagnosed with OSA based on clinical diagnostic testing via laboratory or home-based sleep study;
  • Own and have the functional and cognitive ability to use an Apple (iOS9 or higher) or Android (4.2 or higher) smartphone with minimal to no assistance;
  • Are prescribed continuous or auto-titrated CPAP;
  • Agree to using a smartphone application and wearable wrist sensor; and
  • Speak and read English. 

Exclusion Criteria:

• Exclusion Criteria are the same for both Aim 2 trials
  • Unwilling to complete study measures and engage with SleepWell24;
  • Refuse to not use the Fitbit application during the study trial;
  • Have any conditions that would impede full participation (e.g., communication or cognitive impairments that limit ability to read and/or follow directions, other acute or severe health, cognitive, or psychological conditions);
  • Currently participating in other lifestyle programs (e.g. active, formal weight loss program or research study; smoking cessation program, etc.);
  • Decide to use a different PAP device than ResMed Airsense 10;
  • Prescribed high-dose benzodiazepines (equivalent to > 1 mg lorazapam/night);
  • Daily opioid medication use at night;'
  • Unwilling to discontinue use of any current wearable sensor for the duration of the trial;
  • Previous documented history of treatment/referral for claustrophobia;
  • Previous CPAP use;
  • Currently engaging in shiftwork defined as night shift or rotating day and night shifts; and
  • Currently pregnant, trying to conceive, or breastfeeding.

Note: Other protocol defined Inclusion/Exclusion Criteria may apply.

Eligibility last updated 6/22/23. Questions regarding updates should be directed to the study team contact.